Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000872169 | SCV001013950 | benign | Proline dehydrogenase deficiency | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001536039 | SCV001752732 | likely pathogenic | Proline dehydrogenase deficiency; Schizophrenia 4 | 2021-06-30 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000872169 | SCV002577366 | uncertain significance | Proline dehydrogenase deficiency | 2022-05-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004689909 | SCV005186055 | uncertain significance | not specified | 2024-05-02 | criteria provided, single submitter | clinical testing | Variant summary: PRODH c.1217C>T (p.Pro406Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0019 in 250696 control chromosomes in the gnomAD database, including 2 homozygotes. c.1217C>T has been reported in the literature in individuals affected with Hyperprolinemia (example: DiRosa_2014, Jacquet_2005, Raux_2007). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal activity (Bender_2005). The following publications have been ascertained in the context of this evaluation (PMID: 15662599, 18197084, 15494707, 17135275). ClinVar contains an entry for this variant (Variation ID: 702852). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |